Hengrui Medicine
恒瑞医药
Hengrui Medicine is a pharmaceutical company where Chen Kan serves as team leader . elsewhere's corpus does not cover additional details about its business scope, history, or market position.
AI-generated — may contain errors, please verify.
Coverage
Deep Potential Technology's 800 Million Yuan Raise: From Research Workshop to China's DeepMind
Six key short stories.
暗涌Waves·5Y News｜Minghui Pharma Closes $131 Million Pre-IPO Round to Accelerate Pipeline Development and Global Expansion
Dedicated to developing innovative therapies that address unmet clinical needs worldwide.
五源资本·Deep Dive: China's "DeepSeek Moment" in Biotech | FreeS Fund Report
A Watershed Year for China's Innovative Drug Industry
峰瑞资本·Four Decades of China's Healthcare System: A Journey from Past to Future | FreeS Fund Report
Finding Innovation Opportunities Behind Transformation
峰瑞资本·Fu Wei, who spent ten years doing control buyouts, said they are the blue-collar workers of the investment industry.
Go with the flow.
暗涌Waves·Qiming Venture Partners' Kan Chen: There's an Optimal Path for Chinese Innovative Drugs Going Global
Move beyond single concepts and invest in "global biotech."
暗涌Waves·Everything Has Two Sides: How Can "Nuclear Radiation" Be Used to Make Anti-Cancer Drugs? | FreeS Report 28
Now is the spring of radiopharmaceuticals.
峰瑞资本·What Are the Opportunities for Biotech Over the Next Decade? | A FreeS Fund Conversation
Breaking Through the "Great Stagnation" in Technology: Biotechnology Is a Critical Breakthrough
峰瑞资本·In Our Sixth Year, FreeS Fund Is Hiring Investors | Let's Do What's Right, Not What's Easy
Betting on the power of innovation, staying research-driven.
峰瑞资本·The Hammer and the Dance: Where Healthcare Investment Goes Next Under COVID-19 | FreeS Fund
The unexpected arrival of COVID-19 turned out to be a shot in the arm for the healthcare industry.
峰瑞资本·
